Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Target Price at $9.66

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) have been given a consensus rating of “Hold” by the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $9.66.

Several research firms have weighed in on RVNC. HC Wainwright reiterated a “neutral” rating and set a $6.60 target price on shares of Revance Therapeutics in a research note on Friday, November 8th. Stifel Nicolaus lowered their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, August 9th. William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a report on Monday, August 12th. StockNews.com assumed coverage on Revance Therapeutics in a report on Monday. They set a “hold” rating for the company. Finally, Guggenheim reissued a “neutral” rating on shares of Revance Therapeutics in a report on Monday, August 12th.

Revance Therapeutics Stock Performance

Shares of Revance Therapeutics stock opened at $3.99 on Tuesday. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $9.74. The firm’s 50-day simple moving average is $5.41 and its 200-day simple moving average is $4.45.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. As a group, equities research analysts expect that Revance Therapeutics will post -1.54 earnings per share for the current year.

Hedge Funds Weigh In On Revance Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RVNC. BNP Paribas Financial Markets boosted its position in Revance Therapeutics by 342.1% during the 1st quarter. BNP Paribas Financial Markets now owns 211,695 shares of the biopharmaceutical company’s stock worth $1,042,000 after acquiring an additional 163,809 shares during the period. Swiss National Bank grew its position in Revance Therapeutics by 18.2% in the 1st quarter. Swiss National Bank now owns 194,650 shares of the biopharmaceutical company’s stock valued at $958,000 after buying an additional 30,000 shares in the last quarter. NorthRock Partners LLC acquired a new position in Revance Therapeutics during the 1st quarter valued at about $151,000. Inspire Investing LLC raised its position in shares of Revance Therapeutics by 68.1% during the 1st quarter. Inspire Investing LLC now owns 73,160 shares of the biopharmaceutical company’s stock worth $360,000 after buying an additional 29,645 shares in the last quarter. Finally, Blair William & Co. IL lifted its stake in shares of Revance Therapeutics by 3.6% in the 1st quarter. Blair William & Co. IL now owns 329,267 shares of the biopharmaceutical company’s stock worth $1,620,000 after acquiring an additional 11,318 shares during the period. 97.70% of the stock is owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.